{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T00:08:12Z","timestamp":1788998892208,"version":"build-2803163510"},"reference-count":17,"publisher":"Oxford University Press (OUP)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,8,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Gonorrhea is the second most commonly reported notifiable condition in the United States. Infrequently, Neisseria gonorrhoeae can cause disseminated gonococcal infection (DGI). Eculizumab, a monoclonal antibody, inhibits terminal complement activation, which impairs the ability of the immune system to respond effectively to Neisseria infections. This series describes cases of N. gonorrhoeae infection among patients receiving eculizumab.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Pre- and postmarketing safety reports of N. gonorrhoeae infection in patients receiving eculizumab worldwide were obtained from US Food and Drug Administration safety databases and the medical literature, including reports from the start of pivotal clinical trials in 2004 through 31 December 2017. Included patients had at least 1 eculizumab dose within the 3 months prior to N. gonorrhoeae infection.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Nine cases of N. gonorrhoeae infection were identified; 8 were classified as disseminated (89%). Of the disseminated cases, 8 patients required hospitalization, 7 had positive blood cultures, and 2 required vasopressor support. One patient required mechanical ventilation. Neisseria gonorrhoeae may have contributed to complications prior to death in 1 patient; however, the fatality was attributed to underlying disease per the reporter.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Patients receiving eculizumab may be at higher risk for DGI than the general population. Prescribers are encouraged to educate patients receiving eculizumab on their risk for serious gonococcal infections and perform screening for sexually transmitted diseases (STDs) per the Centers for Disease Control and Prevention STD treatment guidelines or in suspected cases. If antimicrobial prophylaxis is used during eculizumab therapy, prescribers should consider trends in gonococcal antimicrobial susceptibility due to emerging resistance concerns.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/cid\/ciy958","type":"journal-article","created":{"date-parts":[[2018,11,7]],"date-time":"2018-11-07T23:14:50Z","timestamp":1541632490000},"page":"596-600","source":"Crossref","is-referenced-by-count":82,"title":["Disseminated Gonococcal Infections in Patients Receiving Eculizumab: A Case Series"],"prefix":"10.1093","volume":"69","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2803-4264","authenticated-orcid":false,"given":"Page E","family":"Crew","sequence":"first","affiliation":[{"name":"Division of Pharmacovigilance, Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research, United States Food and Drug Administration, Silver Spring, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Winston E","family":"Abara","sequence":"additional","affiliation":[{"name":"Division of Sexually Transmitted Disease (STD) Prevention, National Center for Human Immunodeficiency Virus (HIV)\/AIDS, Viral Hepatitis, STD and Tuberculosis Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynda","family":"McCulley","sequence":"additional","affiliation":[{"name":"Division of Pharmacovigilance, Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research, United States Food and Drug Administration, Silver Spring, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter E","family":"Waldron","sequence":"additional","affiliation":[{"name":"Division of Pharmacovigilance, Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research, United States Food and Drug Administration, Silver Spring, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert D","family":"Kirkcaldy","sequence":"additional","affiliation":[{"name":"Division of Sexually Transmitted Disease (STD) Prevention, National Center for Human Immunodeficiency Virus (HIV)\/AIDS, Viral Hepatitis, STD and Tuberculosis Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily J","family":"Weston","sequence":"additional","affiliation":[{"name":"Division of Sexually Transmitted Disease (STD) Prevention, National Center for Human Immunodeficiency Virus (HIV)\/AIDS, Viral Hepatitis, STD and Tuberculosis Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyle T","family":"Bernstein","sequence":"additional","affiliation":[{"name":"Division of Sexually Transmitted Disease (STD) Prevention, National Center for Human Immunodeficiency Virus (HIV)\/AIDS, Viral Hepatitis, STD and Tuberculosis Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S Christopher","family":"Jones","sequence":"additional","affiliation":[{"name":"Division of Pharmacovigilance, Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research, United States Food and Drug Administration, Silver Spring, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan J","family":"Bersoff-Matcha","sequence":"additional","affiliation":[{"name":"Division of Pharmacovigilance, Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research, United States Food and Drug Administration, Silver Spring, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2018,11,12]]},"reference":[{"key":"2019080101003868500_CIT0001","first-page":"1","article-title":"Sexually transmitted diseases treatment guidelines, 2015","volume":"64","author":"Workowski","year":"2015","journal-title":"MMWR Recomm Rep"},{"key":"2019080101003868500_CIT0002","volume-title":"Sexually transmitted diseases surveillance, 2016","author":"Centers for Disease Control and Prevention"},{"key":"2019080101003868500_CIT0003","first-page":"627","article-title":"Gonococcal infections in the adult","volume-title":"Sexually transmitted diseases","author":"Hook","year":"2008","edition":"4"},{"key":"2019080101003868500_CIT0004","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/j.idc.2005.07.003","article-title":"Gonococcal arthritis (disseminated gonococcal infection)","volume":"19","author":"Rice","year":"2005","journal-title":"Infect Dis Clin North Am"},{"key":"2019080101003868500_CIT0005","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1097\/AOG.0b013e318244eda9","article-title":"Disseminated gonococcal infection in women","volume":"119","author":"Bleich","year":"2012","journal-title":"Obstet Gynecol"},{"key":"2019080101003868500_CIT0006","doi-asserted-by":"crossref","first-page":"60","DOI":"10.3947\/ic.2015.47.1.60","article-title":"Disseminated gonococcal infection presenting as bacteremia and liver abscesses in a healthy adult","volume":"47","author":"Lee","year":"2015","journal-title":"Infect Chemother"},{"key":"2019080101003868500_CIT0007","volume-title":"Drugs@FDA: Soliris (BLA 125166)","author":"US Food and Drug Administration","year":"2018"},{"key":"2019080101003868500_CIT0008","volume-title":"Soliris (eculizumab) [package insert]","year":"2018"},{"key":"2019080101003868500_CIT0009","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1182\/blood-2017-05-781450","article-title":"Eculizumab treatment and impaired opsonophagocytic killing of meningococci by whole blood from immunized adults","volume":"130","author":"Konar","year":"2017","journal-title":"Blood"},{"key":"2019080101003868500_CIT0010","doi-asserted-by":"crossref","first-page":"734","DOI":"10.15585\/mmwr.mm6627e1","article-title":"High risk for invasive meningococcal disease among patients receiving eculizumab (Soliris) despite receipt of meningococcal vaccine","volume":"66","author":"McNamara","year":"2017","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2019080101003868500_CIT0011","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1097\/INF.0b013e3182503849","article-title":"Gonococcal septic shock associated with eculizumab treatment","volume":"31","author":"Gleesing","year":"2012","journal-title":"Pediatr Infect Dis J"},{"key":"2019080101003868500_CIT0012","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1097\/OLQ.0000000000000202","article-title":"Disseminated gonococcal infection and eculizumab\u2014a \u201chigh risk\u201d connection","volume":"41","author":"Hublikar","year":"2014","journal-title":"Sex Transm Dis"},{"key":"2019080101003868500_CIT0013","doi-asserted-by":"crossref","first-page":"E1558","DOI":"10.1503\/cmaj.170508","article-title":"Risks of novel therapeutics: gonococcemia in an immune-suppressed patient receiving eculizumab","volume":"189","author":"Khandelwal","year":"2017","journal-title":"CMAJ"},{"key":"2019080101003868500_CIT0014","volume-title":"Questions and answers on FDA\u2019s adverse event reporting system (FAERS)","author":"US Food and Drug Administration"},{"key":"2019080101003868500_CIT0015","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15585\/mmwr.ss6507a1","article-title":"Neisseria gonorrhoeae antimicrobial susceptibility surveillance\u2014the gonococcal isolate surveillance project, 27 sites, United States, 2014","volume":"65","author":"Kirkcaldy","year":"2016","journal-title":"MMWR Surveill Summ"},{"key":"2019080101003868500_CIT0016","doi-asserted-by":"crossref","first-page":"830","DOI":"10.3201\/eid2305.170088","article-title":"Azithromycin resistance and decreased ceftriaxone susceptibility in Neisseria gonorrhoeae, Hawaii, USA","volume":"23","author":"Papp","year":"2017","journal-title":"Emerg Infect Dis"},{"key":"2019080101003868500_CIT0017","volume-title":"MedWatch: the FDA safety information and adverse event reporting program","author":"US Food and Drug Administration","year":"2018"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/cid\/article-pdf\/69\/4\/596\/29022076\/ciy958.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T01:00:54Z","timestamp":1564621254000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/69\/4\/596\/5173471"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,12]]},"references-count":17,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2018,11,12]]},"published-print":{"date-parts":[[2019,8,1]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciy958","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,8,15]]},"published":{"date-parts":[[2018,11,12]]}}}